Aims: The crossing of chronic total occlusions (CTOs) is the key step for an endovascular treatment. The Ocelot system is a novel device that combines a steerable drilling tip with optical coherence tomography (OCT) technology. It provides intraluminal imaging to help the crossing of CTOs in the femoropopliteal segment. Aim of the study was to determine early and midterm results after recanalization with this device. Methods and Results: During a period of 16 months, 84 CTOs were treated using the Ocelot system and prospectively registered. The primary end points were technical success and the primary and secondary patency of the lesion. Risk factors associated with early and midterm results were also analyzed. In all, 58 (69.0%) lesions were treated for intermittent claudication, 26 (31.0%) for critical limb ischemia, 34 (40.5%) were classified as Trans-Atlantic InterSociety Consensus II D lesions, and 22 (26.2%) showed severe calcifications. The technical success rate was 72.6%. During 36 months of follow-up (mean 25.9), there were 10 reinterventions. The primary and secondary patency at 36 months were 54.2% and 68.1%, respectively. Conclusions: In our experience, the Ocelot system would appear to be a safe and effective tool for increasing the applicability of endovascular techniques. However, the midterm results did not show drastic improvement.
Introduction
Peripheral artery disease (PAD) is increasing widespread, and, especially in chronic limb ischemia, it is associated with high costs due to recurrent hospitalization, limb loss, and death. [1] [2] [3] Chronic total occlusion (CTO) of the infra-inguinal arteries defined as classification C and D lesion by the Trans-Atlantic Inter-Society Consensus (TASC II) is a challenge in endovascular treatment. The key step to successful treatment is the crossing of the occluded lesion.
Subintimal recanalization (SIR) is the standard approach, particularly in long lesions. This is a well-known method originally described by Bolia et al in 1989 . 4 No dedicated devices are needed for SIR, but there are lesions that cannot be crossed with SIR and failure rates range from 20% to 30%. [4] [5] [6] Fluoroscopy alone does not allow the visualization of the plaque structure, and navigation through the occluded vessel remains the limiting factor for endovascular technique.
To overcome these limitations and to improve options for endovascular treatment of femoropopliteal CTOs, various catheters and recanalization devices have been developed during recent years. 7 One of the crossing catheters developed was the Wildcat catheter (Avinger, Inc, Redwood City, California) system. It provides a rotating tip with spiral wedges which enable CTO crossing under fluoroscopic control, and a recent report has shown an improved crossing rate. 8 The Ocelot system consists of the Ocelot catheter and the Lightbox console (Avinger, Inc) and offers an alternative solution for visualizing and navigating through occluded vessels. This system combines a crossing catheter equipped with a guidable active rotating tip, like the Wildcat catheter system, to facilitate successful recanalization of CTOs. On the downside, the rotating tip could also cause damage to the vessels, such as perforations when oriented in the wrong direction. In addition, it offers a high-definition intraluminal imaging mode based on optical coherence tomography (OCT) technology, providing real-time intraluminal imaging to assess vessel wall layers and plaque structures. This feature helps the catheter remain in the true lumen while crossing the CTO.
The OCT imaging is a well-known technology and is already in use in various specialities such as ophthalmology, gastroenterology, and dermatology. In cardiology, it allows the assessment of atherosclerosis in coronary arteries. [9] [10] [11] [12] The safety and effectiveness of the Ocelot catheter has recently been evaluated in the CONNECT II study. 13 It was also assumed in the study that this kind of crossing may improve long-term outcomes. At the moment, there are no studies reporting mid-term results using this technology.
The aim of this study is to (1) analyze the the early to midterm efficacy and safety of this new technology and (2) attempt to identify the possible risk factors that may affect these results.
Methods
All patients with CTO of the femoropopliteal axis treated with the Ocelot system between October 2011 and January 2013 were included in the study. The device specification and technique has been previously described.
14 The patients were all over 18 years of age and gave consent to the procedure, and the protocol and consent were approved by the institutional review board.
Baseline evaluation was by physical examination, anklebrachial index (ABI), duplex ultrasound, and computed tomography angiography (CTA) of the lower limbs. All the procedures were performed using a Hybrid-OR with a fixed imaging system (Artis TA, Siemens, Erlangen, Germany) by an experienced operator.
The length of the lesion and the diameter of the vessel were assessed by CTA. The types of lesion were grouped according to the TASC II classification. 15 A subclassification was also provided for lesions shorter than 100 mm. The procedures were usually performed under local anesthesia. Contralateral transfemoral approach was used with a 45 cm 7French sheath placed through the aortic bifurcation in the ipsilateral common femoral artery. Five thousand units unfractioned heparin were administered intraarterial in all patients after femoral artery puncture.
An angiogram was performed to localize the proximal and distal cap of the lesion and the number of runoff vessels below the knee. The amount of calcification was graded in 3 different categories according to the presence of radiopositive calcifications within the vascular wall at the occlusion. The classification included none/mild (no or few radio-opacities noted prior to contrast injection), moderate (multiple radio-opacities noted only prior to contrast injection), and severe (diffuse radioopacities noted on both sides of the arterial wall). 16 The Ocelot system was used based on the single surgeon's experience and discretion, who performed all the interventions, aiming at the reduction in a false road establishment of and to increase the chance of crossing the true lumen. The ability of the device to cross the CTO was defined as technical success. The use of a re-entry device (Outback; Cordis J&J, Fremont, California) to gain the guide wire in the true lumen was defined as an assisted technical success. If the crossing of the lesion was not possible it was defined as failure.
In case of angiographic suboptimal results after simple percutaneous transluminal angioplasty (PTA), stenting (Protégé Everflex, Medtronic, Minneapolis, Minnesota; Supera, Abbot, Lake Bluff, Illinois) or use of endovascular atherectomy devices (Turbohawk, Medtronic, Minneapolis, Minnesota; Rotarex, Straub Medical AG, Wangs, Switzerland) with drug-eluting ballon angioplasty (IN.PACT Admiral, Medtronic, Minneapolis, Minnesota) were adopted either alone or in combination based on the operator's experience.
A double platelet inhibition (100 mg acetylsalicylic acid and 75 mg clopidogrel) was administered for 8 weeks following lifelong single antiplatelet therapy, and statins were prescribed for all patients. Postoperative clinical assessment, ABI and duplex ultrasound were performed before discharge, after 6 months, and yearly. Clinical success was defined as improvement in walking distance, absence of rest pain, or healing of the trophic lesions. Primary and secondary patencies were defined as suggested in the reporting standard of the Society of Vascular Surgery and used as primary end points. 17 
Statistical Analysis
All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) PC version 22 for Windows (IBM Corporation, Armonk, New York). Demographic, intra-and postoperative, and follow-up data of the patients were prospectively recorded. Mean values and standard deviations were calculated for all the variables. The univariate influence of dichotomous variables on failure was determined. The w 2 Test or Fisher exact test was used for comparisons. The influence of male gender, smoking, hypertension, diabetes, obesity, coronary heart disease, previous peripheral interventions, clinical status, type of the lesion, calcification, and popliteal involvement on failure was tested by multivariate analysis.
Patency rates were calculated using Kaplan-Meier method of life-table estimates. Lines were truncated when the standard error exceeded 10%. The association of risk factors with primary outcomes was determined by Cox regression analysis. For each variable, log-linearity tests and proportional hazards models were performed. P values <.05 were considered statistically significant.
Results
During the study period, 272 CTOs of the superficial femoral artery or the popliteal artery were treated at our institution. Of these, 83 patients were treated with the Ocelot system and registered in the study. In 1 patient, both legs were treated and considered separately, resulting in a total of 84 CTO cases.
The mean age was 70 years (+ 10.27) and 49 were men (58.3%). A high rate of active smokers was identified (56%). Additionally, 47 patients (56%) had been treated of PAD in previous interventions. Fifty-eight cases (69%) were treated of intermittent claudication and 26 cases (31%) treated of critical limb ischemia, including rest pain in 14 (16.7%) and tissue loss in 12 (14.3%). The patient's demographic characteristics are summarized in Table 1 .
According to the lesion characteristics, 20 (23.8%) were shorter than 100 mm and 35 (41.7%) were classified as TASC II D, with a mean length of the lesion of 194.8 mm (+ 109.9 mm, range 30-600 mm). In 9 (10.7%) CTOs, the popliteal artery was involved. Heavy calcification of the vessel was found in 22 (26.2%) lesions. Table 2 lists the morphology and characteristics of the lesions.
Technical success was achieved in 61 (72.6%) cases, while in 13 (15.5%) an additional device was needed resulting in a total assisted technical success in 74 of 84 (88.1%) cases. In the remaining cases, including 2 unsuccessful applications of an additional re-entry device, an endovascular approach failed.
Of these 74 CTOs, a recanalization of the vessel was achieved with simple PTA in 16 (21.6%) cases, an atherectomy device was used in 3 cases (4.1%), and stenting of the lesion was needed in 58 (78.4%) cases.
The mean procedure time was 87.9 minutes (+ 27.9 minutes) and mean fluoroscopy time was 25.8 minutes (+ 11.7 minutes). The mean amount of contrast used was 150.5 mL (SD 53.4 mL).
In 4 (4.8%) of the 84 cases complications occurred, which included 4 perforations, and in 1 patient an associated distal embolization. The 3 isolated perforations resolved after stenting or ballooning. In any case, they were not responsible for additional failure. In the case of perforation and embolization, a covered graft was applied and the embolization was treated successfully by locoregional lysis. The univariate and multivariate analyses for failure and intraoperative complication identified heavy calcification and obesity risk factors for technical failure (respectively, odds ratio [OR] 8.8, P ¼ .018 and OR 10.9, P ¼ .011; Table 3 ).
Postoperative assessments revealed a mean increase in ABI of 0.40 (+ 0.24) and an improvement in Rutherford stages of 1.48 (+ 0.94), applicable for patients with claudication and rest pain.
Median follow-up for the 74 successfully treated cases was 25.9 (interquartile range 20.0-32.1) months. During this time, 10 (13.5%) occlusions were found and successfully treated. Two of these cases occured after initial treatment with PTA alone and the others after primary stenting.
According to life-table estimates, primary and secondary patency rates at 36 months were 54.2% and 68.1%, respectively (Figure 1) . The statistical analysis for primary patency identified TASC II D lesions and the intraprocedural use of a re-entry device as the only significant risk factors for arterial reocclusion during follow-up (Table 4 and Figures 2 and 3) . The analysis for secondary patency also identified TASC II D lesions as the only significant risk factor (Table 5 ). The presence of critical limb ischemia represented no significant risk factor for primary or secondary patency.
Discussion
The current study was able to evaluate the feasibility, efficacy, and safety of the endovascular treatment of femoropopliteal lesions with the Ocelot system and to analyze the first midterm results after treatment with the device. The midterm results of the present study show a lasting primary and secondary patency rate of 54.2% and 68.1%, respectively, after 36 months. These data are encouraging, especially considering the high perioperative success rate (72.6% and 88.1% assisted success rate).
The high technical success rate of 72.6% coupled with a low complication rate (4.8%) are among the best evidence of the system's ability to assist the operator also in the case of long occlusions (mean lesion length 194.8 mm). The length of the lesion or its morphology (according to TASC) did not constitute a significant risk factor for technical failure. The high image resolution of the OCT helps to identify the morphology of the occlusion with regard to plaque and calcification of the vessel. Furthermore, there is a learning curve in the handling of the Ocelot system and interpretation of the OCT. As previously shown, the use of the Ocelot system can enable a significant reduction in procedure time, contrast volume, and fluoroscopy time but only after an adequate learning phase. 13 We also learned that in order to minimize the creation of false pathway and to improve early technical success, the Ocelot system should be used not only as bailout option but also as primary option. The actual report was not designed to make this kind of comparison, but some of the reported technical failures occurred in the attempt to use the Ocelot system as the bailout device.
Regarding the safety and efficacy, the findings in this study are comparable with the results of other studies, which investigated the Ocelot system 13, 15 and other new devices for recanalization of CTOs 18 (eg, Wildcat, 8 Frontrunner XP, 19 Crosser, 20 TruePath 21 ). A high technical success rate, ranging from 77% to 100%, is generally reported in these studies along with a low rate of intraprocedural complications (<5%). The difference between groups was significant (P ¼ .019, log-rank test).
On the other hand, SIR using conventional techniques has also been reported with technical success rates up to 80% without additional devices and complication rates ranging 2% to 6%. 6 Calcifications can be well visualized with the OCT, unlike intravascular ultrasound. Kume et al were able to demonstrate the superiority of the OCT in estimating the calcification amount. 22 Nevertheless, we found that heavily calcified lesions remained statistically associated with a higher early failure rate (P ¼ .018). The friction between the catheter and the calcification probably reduces the capability to guide the drilling tip. Similar limitations to the efficacy of the Ocelot and Wildcat systems have been recognized in previous published experiences, in which heavily calcified lesions have been reported as presenting difficulties or have indeed even been excluded from studies. 8, 13, 15 Although the OCT is a powerful tool for navigating through the occluded vessel and despite what was previously assumed, 13 our study did not show a drastic improvement in the patency rate also in the midterm. Comparing our results with previous published studies using SIR combined or not with stenting, no significant difference was evident. A study investigating the midterm and long-term results of SIR with routine stenting showed primary patency rates for 1 and 3 years of 84% and 67%, respectively. 23 A meta-analysis of literature between 2000 and 2007 focusing on femoropopliteal occlusive disease showed a 1-year patency for PTA from 45% to 84% and for stenting from 63% to 90%. The 2-year patency rates ranged from 46% to 87%. 24 The 2-year patency rates in our study were 72.4% for primary and 81.5% for secondary patency. Recanalization with the Excimer Laser-assisted technique, designed to provide an option for the recanalization of CTOs, showed 1-year assisted-primary and secondary patency rates of 65.1% and 75.9%, respectively. 25 However, our experience shows that we were able to extend the endovascular indication also in difficult lesions and a primary patency rate of 54.2% after 36 months is an indicator of a lasting result, probably related more closely to the use of a stent. The high technical success rate, despite the unchanged midterm patency of the lesion, means it can be considered as offering a significant opportunity for those patients with distal ulcers, requiring an improved distal perfusion only for the time needed for the healing of the trophic lesion. A CTO recanalization might successfully postpone, if not avoid, a more invasive conventional bypass.
The patency rate probably depends more on the kind of the stents, atherectomy devices, and the use of drug coated balloons (DCBs) rather than the quality of crossing. It may suggest that the length of the lesion and thus the length or number of implanted stents may constitute the main factor regarding midterm and long-term performance after successful recanalization and treatment. Poorer midterm and long-term results for TASC II C and D lesions treated by nitinol stents have been described previously. 26 A linear decrease of 1-year primary patency in longer femoropopliteal lesions treated with nitinol stents was reported, especially for lesions longer than 250 mm. 27 Initially, after crossing with the Ocelot system, we tended to perform a simple PTA. This was supported by the assumption that a "true-lumen" recanalization can offer lasting results also without the need of additional devices. Lesions that were primarily treated by balloon angioplasty alone after recanalization showed a frequent recurrence of occlusion and could be treated by re-PTA and stenting. This might support the results of an earlier comparison of primary stenting versus PTA with optional stenting in femoropopliteal obstructions showing a sustained benefit in the first 12 months of primary stenting. 28, 29 We quickly moved on from the concept of simple PTA alone and began to combine it with the use of nitinol stents and recently also with atherectomy, combined with or without DCB.
As shown by several reports, atherectomy followed by angioplasty with DCB is probably one of the most promising research areas in the treatment of femoropopliteal lesions. [30] [31] [32] [33] We should consider that the Ocelot system may offer an ideal Recently a further development of the Ocelot system and combining atherectomy device with OCT (Pantheris System; Avinger, Inc) has been introduced and evaluated in the VISION study, showing an increased plaque removal and less adventitial damage. 35 The goal is to reduce the relatively high incidence of vessel rupture associated with atherectomy, reported as up to 6%, 36 and to improve the quality of recanalization, especially in eccentric plaque. In fact, live OCT imaging during atherectomy can prevent adventitial damage leading to perforation and the consequential effects of an excessive inflammatory response. Atherectomy followed by angioplasty with DCBs might help to overcome the occurrence of intimal hyperplasia, which often occurs after stenting and compromises the midterm and long-term results. 37, 38 This could lead to better midterm and long-term patency, reducing the limitation due to stenting, especially in long lesions.
Limitations
Several limitations affected our single-center study, some of which must be specified. There are various operating surgeons in our center, but very few had been trained in this procedure and only 1 single surgeon performed these cases registered in this study. This exposes our study to a selection bias. Also, the experience-based indication for the Ocelot system varies from bailout technique to primary use.
Conclusions
Early results indicate that the Ocelot system is an effective device that may increase the endovascular options in CTO of the femoropopliteal arterial district, also when conventional technique fails. However, the system does not seem to drastically improve midterm patency. In the future, the combination of adjunctive procedures like atherectomy and/or DCBs might lead to better midterm and long-term patency, reducing the limitations imposed by stenting, especially in long lesions.
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